Talk:Exact Sciences Corp.

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Edit Request[edit]

NOTE: I am proposing this edit for FleishmanHillard on behalf of Exact_Sciences_(company). I am a paid editor and am aware of the COI guidelines. I am submitting this edit request to propose revisions and additions to the article that reflect new information in hopes of making the article more current and up-to-date. I have outlined the proposed edits below by section, with the proposed new copy below the outline in the extended content. I also included all current and new sources within the proposed copy. Thank you for your consideration.

  1. Infobox
    1. Under Key People, please add Graham Lidgard (Chief Science Officer).
    2. Under “Products,” we would like to add Cologuard before “a non-invasive, Multitarget stool DNA screening test. Cologuard is Exact Sciences best known product and may have equity with those seeking information about the company.”
    3. For “Number of employees,” Exact Sciences’ team has grown to ~1,000.
  2. Upfront
    1. Please slightly revise first sentence to change “colorectal cancer” to “cancers.” Though primarily known for their work in the colorectal cancer space, Exact Sciences is actively working on detection and prevention of multiple cancer types.
  3. Products
    1. Proposed new copy below intended to provide more detail on how Cologuard (the at-home stool DNA screening test) works and its indication (for adults 50 years and older).
    2. Proposed new copy also provides additional details on the lung cancer tests currently in development.
  4. Company Events
    1. Revised header from “Note Worthy Company Events” to “Company Events” to correct misspelling of “noteworthy.”
    2. Added additional key company milestones occurring in 2001, 2009, 2014 and 2018.
  5. Awards
    1. Added in one additional award for 2017.
Extended content
Exact Sciences Corporation
Company typePublic (Nasdaq: EXAS)
IndustryMolecular diagnostics
Founded1995 in Marlborough, Massachusetts
HeadquartersMadison, Wisconsin, USA
Key people
Kevin Conroy
(Chairman, President & CEO) [1] Graham Lidgard
(Chief Science Officer)[2]
ProductsCologuard, a non-invasive, Multitarget stool DNA screening test [3]
Number of employees
~1,000 (2017[4])
WebsiteExactSciences.com

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of cancers. The company was founded in 1995 in Marlborough, Massachusetts and today is headquartered in Madison, Wisconsin. [5]

References

  1. ^ "Kevin Conroy Chairman/President/CEO, Exact Sciences Corp". Bloomberg. Retrieved June 20, 2018.
  2. ^ "Graham Lidgard Chief Science Ofcr, Exact Sciences Corp". Bloomberg. Retrieved June 20, 2018.
  3. ^ Cologuard Patient Guide (PDF) (Report). 2013. Retrieved June 20, 2018.
  4. ^ David Schuyler (November 15, 2017). "Exact Sciences breaks ground on lab, office expansions in Madison". Milwaukee_Business_Journal. Retrieved February 20, 2018.
  5. ^ Ryan McBride (June 18, 2009). "Exact Sciences Moving to Wisconsin". Xconomy. Retrieved September 9, 2015.

Products[edit]

In August 2014, the U.S. Food and Drug Administration (FDA) approved Cologuard, a non-invasive colorectal screening test for adults 50 years and older. [1] The test is a stool-based deoxyribonucleic acid (sDNA) screening test, which detects deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. [2]

Exact Sciences continues to pursue the development of other cancer detection tests. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a CT or other scan. [3]

References

  1. ^ CBS and Associated Press (October 23, 2016). "FDA approves first DNA test for colon cancer". Bloomberg. Retrieved May 31, 2018.
  2. ^ Vijeta Pamudurthy, Marc Bissonnette and Vani Konda (February 10, 2016). "Biomarkers in Colorectal Cancer Screening". Journal of Gastrointestinal & Digestive System. {{cite journal}}: Cite journal requires |journal= (help)
  3. ^ "Exact Sciences Corp". Financial Times. Retrieved June 20, 2018.

Company Events[edit]

  • 2001 – Initial Public Offering on NASDAQ (US).[1]
  • 2009 - Kevin Conroy joins Exact Sciences as CEO & President.[2]
  • 2009 – Exact Sciences and Mayo Clinic collaboration established.[3]
  • 2014 – FDA approval and CMS coverage for Cologuard.[4]
  • 2018 - Exact Sciences completes a $690 million convertible bond offering.[5]
  • 2018 – Exact Sciences completes 1 million Cologuard tests.[8]

References

  1. ^ "Exact Sciences". Crunchbase. Retrieved June 20, 2018.
  2. ^ "Exact Sciences Corp". Bloomberg. Retrieved June 20, 2018.
  3. ^ "Exact Sciences Licenses Mayo Clinic IP; Closes $8.2M Placement". GenomeWeb]]. June 12, 2009.
  4. ^ Elaine Schattner (March 6, 2015). "For Colon Cancer Screening, Cologuard Test Offers A Solid New Option". Forbes.
  5. ^ "XMS Capital Partners Serves as Financial Advisor to Exact Sciences on $600 Million Convertible Notes Offering". January 24, 2018.
  6. ^ "XMS Capital Partners Serves as Financial Advisor to Exact Sciences on $600 Million Convertible Notes Offering". January 24, 2018.
  7. ^ "Exact Sciences (EXAS) Reports Offering of $500 Million Convertible Senior Notes Due 2025". January 11, 2018.
  8. ^ Judy Newman (March 3, 2018). "Exact Sciences' Cologuard reaches 1 million milestone". Wisconsin State Journal.


Awards[edit]

Exact Sciences received a 2015 American Business Awards Gold Stevie for Company of the Year in the Health Products & Services category.[1]

Exact Sciences Corp. won 2016 10th Annual Prix Galien USA Award for best medical technology product. [2]

The company received the Business Intelligence Group’s 2016 Company of the Year BIG Award for Business in the Health Care category.[3]

In 2017, the company was awarded a Wisconsin Manufacturer of the Year Special Award for Exceptional Growth & Service. [4]


References

  1. ^ "2015 Company/ Organization Awards Categories Stevie® Award Winners". The American Business Awards. Retrieved 9 September 2015.
  2. ^ Galien Foundation. "2016 Prix Galien Awards". Retrieved October 31, 2016.
  3. ^ Business Intelligence Group. "BIG Awards for Business 2016". Winners of the 2016 Business Awards. Retrieved October 31, 2016. {{cite web}}: |last1= has generic name (help)
  4. ^ "Wisconsin Manufacturer of the Year; All Award Winners in Program History". Retrieved June 20, 2018.

Category:Companies listed on NASDAQ

Jon Gray (talk) 22:06, 26 June 2018 (UTC) Thank you for considering these edits.[reply]


Reply to edit request 26-JUN-2018[edit]

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes for information on each request.  spintendo  23:30, 26 June 2018 (UTC)[reply]

Requested edit review 26-JUN-2018

Under Key People, please add Graham Lidgard (Chief Science Officer).
 Approved.[note 1]

___________
Under "Products," we would like to add Cologuard before "a non-invasive, Multitarget stool DNA screening test." Cologuard is Exact Sciences best known product and may have equity with those seeking information about the company.
 Approved.[note 2]

___________
For “Number of employees,” Exact Sciences’ team has grown to ~1,000.
 Approved.[note 3]

___________
Please slightly revise first sentence to change “colorectal cancer” to “cancers.” Though primarily known for their work in the colorectal cancer space, Exact Sciences is actively working on detection and prevention of multiple cancer types.
no Not approved.[note 4]

___________
Proposed new copy below intended to provide more detail on how Cologuard (the at-home stool DNA screening test) works and its indication (for adults 50 years and older). Proposed new copy also provides additional details on the lung cancer tests currently in development.
no Not approved.[note 5]

___________
Company Events Revised header from “Note Worthy Company Events” to “Company Events” to correct misspelling of “noteworthy.”
 Partly approved.[note 6]

___________
Added additional key company milestones occurring in 2001, 2009, 2014 and 2018.
 Partly approved.[note 7]

___________
Awards: Added in one additional award for 2017.
no Not approved.[note 8]

___________

  1. ^ This change was made in the infobox.
  2. ^ This change was added to the prose and to the infobox.
  3. ^ This change was added to the infobox.
  4. ^ This part of your proposal involves information concerning the company's future products, and as such, is not germane to the article. (See WP:NOTCRYSTALBALL.)
  5. ^ The proposed text in these sections is insufficiently paraphrased from the source material.[1] All text which is to be placed into an article needs to be phrased using an editor's own words and should be written using an editor's own phrasing. (See WP:CLOSEPARAPHRASE.)
  6. ^ This heading was changed to Milestones.
  7. ^ Certain items were added to this list. Other items concerning auxiliary events were omitted (i.e., Bank of America's role as book-running manager, etc.).
  8. ^ Claims concerning awards received represents subjective information which, if to be added, should contain secondary sources.

References

  1. ^ Copyvio Detector. "List of Insufficiently Paraphrased Text - Exact Sciences Edit Request". tools.wmflabs.org. Retrieved 26 June 2018.

Edit Request[edit]

NOTE: I am proposing this edit for FleishmanHillard on behalf of Exact_Sciences_(company). I am a paid editor and am aware of the COI guidelines.

With regard to my recent edit request on June 26, 2018, I wanted to submit additional information to hopefully address two areas that were declined.

First, regarding additional detail on Cologuard, the original submission was rejected due to WP:CLOSEPARAPHRASE (note 5). We have revised the proposed copy as follows and request a small addition to the sentence as it currently stands to make the test’s indication clear. With the proposed addition included (and fourth source added to reference the addition), the current sentence would now read as follows:

In August 2014, the U.S. Food and Drug Administration (FDA) approved the company’s at-home multitarget stool DNA screening test called Cologuard, for the detection of colorectal cancers and pre-cancers. The test is indicated for adults age 50 and older in accordance with the United States Preventive Services Task Force’s recommendations for colorectal cancer screening. [1][2][3] [4]

Regarding note 8, which accompanied a rejection of an added company award, we have identified two news sources that confirm Exact Sciences was given the Wisconsin Manufacturer of the Year Special Award for Exceptional Growth & Service. The first can be found in an article in the Milwaukee Business News (https://www.biztimes.com/2018/industries/manufacturing-logistics/milwaukee-area-firms-shut-out-of-manufacturer-of-the-year-awards/). The second is found in an article from the Wisconsin_State_Journal (https://host.madison.com/wsj/business/manufacturer-of-the-year-awards-honor-two-local-businesses/article_08bafb23-21bc-5eb6-bcbe-7a9d7c5fc519.html).

With these sources cited, please let us know if you’re agreeable to reversing your original rejection for the Wisconsin Manufacturer of the Year Special Award addition. Jon Gray (talk) 23:15, 17 July 2018 (UTC)Thank you for considering these additions.[reply]

References

  1. ^ "FDA approves first non-invasive DNA screening test for colorectal cancer". U.S. Food and Drug Administration. FDA. Retrieved 9 September 2015.
  2. ^ Edney, Anna (August 12, 2014). "Exact Sciences Wins U.S. Approval for Colon Cancer Test". Bloomberg. Retrieved 9 September 2015.
  3. ^ Schattner, Elaine (March 6, 2015). "For Colon Cancer Screening, Cologuard Test Offers A Solid New Option". Forbes. Retrieved 9 September 2015.
  4. ^ Vijeta Pamudurthy, Marc Bissonnette and Vani Konda (February 10, 2016). "Biomarkers in Colorectal Cancer Screening". Journal of Gastrointestinal & Digestive System. {{cite journal}}: Cite journal requires |journal= (help)

Reply 17-JUL-2018[edit]

check Request partially-implemented
  1. Red XN The re-worded sentence regarding the subject's product could not be added to the article, as the journal submitted as a reference was identified as a predatory open access journal (Journal of Gastrointestinal & Digestive System). Sources of this type and the claims they reference are routinely removed from Wikipedia. If the same information were to be found in another academic source from a more reputable journal as advised in WP:MEDRS the claim might be acceptable. (Its phrasing, in any event, is acceptable – and I thank you for altering it.)
  2. Green tickY The claim regarding the "Wisconsin Manufacturer of the Year Special Award for Exceptional Growth & Service" is referenced by Wisconsin-only sources which, arguably, are not independent. These were nevertheless appended along with the claim to the milestones section.
  3. Additionally, a Vague Inline Maintenance Template was added to the claim regarding the "Mayo collaboration", as this claim requires elucidation.
Regards,  spintendo  04:04, 18 July 2018 (UTC)[reply]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Exact_Sciences_Corp.&oldid=1222024923"